NICE’s Position on AI in Evidence Generation

By João L. Carapinha

November 18, 2024

The National Institute for Health and Care Excellence (NICE) has issued a position statement on the use of artificial intelligence (AI) in evidence generation. This statement clarifies what NICE expects when incorporating AI methods for evidence generation and reporting. The guidance emphasizes the necessity for transparency, rigor, and trust throughout the evidence generation process.

Key Objectives and Expectations

The position statement outlines NICE’s expectations regarding AI methods in evidence generation. It highlights the importance of adhering to existing regulations, good practices, and guidelines when utilizing AI methods.

Benefits of AI in Evidence Generation

AI methods, such as machine learning and generative AI, can efficiently handle large datasets, reveal patterns, and produce novel outputs beneficial for evidence synthesis. This capability can significantly enhance clinical evidence, trial design, systematic reviews, real-world data analysis, and cost-effectiveness studies.

Transparency and Justification

When AI is employed, it is essential for reporting to be transparent. NICE advises using established checklists like PALISADE to justify AI application and TRIPOD+AI to outline AI model development. Any AI approach must be treated as part of the clinical trial, with comprehensive details provided in the submission.

Human Involvement and Oversight

NICE emphasizes that AI should enhance human involvement, not replace it. Human oversight is vital to validate AI-generated outputs and to mitigate risks like algorithmic bias.

Specific Applications of AI

AI can streamline conventional literature search and review processes, covering search strategies, study classification, primary and full-text screening, and visualizing search results. Also, large language models (LLMs) can automate data extraction and generate code for synthesizing gathered data.

In real-world data analysis, AI supports various evidence generation stages, including updating economic models with newly acquired information.

Engagement with NICE

Organizations looking to leverage AI methods should engage with NICE to review their plans. Initial engagement can occur through NICE Advice, with further discussions involving the appropriate NICE technical teams taking place in later stages.

Future Considerations

NICE recognizes that other institutions, like Cochrane and the Guidelines International Network, are also developing guidelines for responsible AI use in evidence synthesis. This trend indicates greater integration of AI in health technology assessments (HTA).

In conclusion, NICE’s position on AI in evidence generation emphasizes its potential benefits while stressing the importance of transparency, human oversight, and strict adherence to existing standards and regulations to ensure the effectiveness and trustworthiness of AI methods.

Reference url

Recent Posts

semaglutide NAION risk
    

Semaglutide NAION Risk: EMA Review Initiated Amid Conflicting Evidence

🔍 Is semaglutide linked to vision loss?

The European Medicines Agency’s PRAC is currently reviewing the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing medicines, including popular treatments like Ozempic and Wegovy. With recent studies yielding conflicting evidence, this review is crucial for patient safety and the future of these therapies.

Read the full article to understand the implications and what this could mean for healthcare providers and patients alike!

#SyenzaNews #Pharmaceuticals #HealthcarePolicy

cervical cancer screening
        

Cost-Effective Cervical Cancer Screening Strategies for Women with HIV in KwaZulu-Natal

💡 *Are single-visit cervical cancer screenings the key to better health outcomes in high HIV prevalence areas?*
A recent study from KwaZulu-Natal, South Africa reveals that repeat single-visit cervical cancer screening using HPV DNA testing is not only the most effective but also the most cost-effective approach for women living with HIV. This aligns with WHO recommendations for comprehensive cervical cancer elimination strategies.

Explore the insights and implications of this vital research that could transform cervical cancer prevention in resource-limited settings.

#SyenzaNews #HealthEconomics #oncology #GlobalHealth

EU Health Technology Assessment
          

Advancing EU Health Technology Assessment: Insights from the HAG Meeting

💡 How can the EU Health Technology Assessment reshape healthcare delivery?

The recent meeting of the Heads of HTA Agencies Group heralds a new era with the operationalization of the EU’s Health Technology Assessment Regulation, aiming to streamline processes and enhance collaboration across member states.

This initiative promises to improve data transparency, foster innovative health technologies, and ultimately, drive better patient outcomes.

Curious to learn more about these significant updates and what they mean for the future of health assessments in the EU? Jump into the full article!

#SyenzaNews #HealthTech #HealthEconomics #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.